Adolore Biotherapeutics Enters into Exclusive License Agreement with University of Pittsburgh for Patents Protecting Non-Toxic Replication-Defective HSV Vectors for Efficient Gene Delivery Applications and Complementing Cells for Their Production

Company developing next generation, disease-modifying, non-opioid analgesic gene therapies for the treatment of chronic painDELRAY BEACH, FL / May 23, 2023 / Adolore Biotherapeutics, Inc. (“Adolore” or the “Company”) a biotechnology company...